Navigation Links
Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
Date:10/4/2007

Adlea May Provide Pain Relief Without Opiate-Like Side Effects For Weeks to

Months Following a Single Administration

SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the first patient has been treated in a Phase 2 study of the company's compound Adlea(TM) (formerly 4975) for post-operative pain in patients who undergo total hip replacement surgery, also called Total Hip Arthroplasty (THA). Adlea is a long-acting, non-opiate analgesic drug candidate designed to provide pain relief for weeks to months after a single local application during the surgical procedure.

"Hip replacement surgery can involve a long recovery time -- sometimes up to six months -- which is frequently accompanied by post-operative pain from the procedure," said John P. McLaughlin, chief executive officer of Anesiva. "We believe Adlea may help alleviate the resulting pain for patients without the troubling side effects that other treatments such as opiates and COX-2 inhibitors can cause. We believe that these benefits can help patients recover faster and complete their rehabilitation more successfully after surgery."

The trial will enroll approximately 160 patients, randomized to receive either a single 15-mg dose of Adlea or placebo instilled into the surgical wound prior to closure. The trial will evaluate safety, tolerability, pharmacokinetics, and the ability of Adlea to reduce post-operative pain following total hip replacement surgery.

Anesiva previously announced positive data from a Phase 2 study showing that a single treatment with Adlea in patients undergoing total knee replacement surgeries produced significant reduction in pain on ambu
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... , , , ... announced the start of a phase II human clinical trial of ... people with diabetes mellitus. The randomized, controlled 12-week trial in patients ... Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, ...
... Potential to Treat a Broad Spectrum of Migraine,***UPDATED SATELLITE ... common, debilitating neurological disorder that affects,approximately 30 million people ... Limitations of oral triptans, the class of,prescription drugs widely ... between 45 and 90 minutes, substantial variability in,patient response ...
Cached Medicine Technology:Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes 2MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS 2
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Losing weight can help reduce your risk of cancer if ... effective in lowering that risk, an expert says. Diets ... changes in eating habits and also provide a variety of ... clinical dietitian in the clinical nutrition department at the University ...
... Urinary tract infections are common in women, costing an ... in the United States alone. These infections frequently ... A depletion of vaginal lactobacilli, a type of ... suggests that replenishing these bacteria may be beneficial. Researchers ...
... , cancer scientists Ana Soto and Carlos Sonnenschein pit their ... cancer against the widely accepted Somatic Mutation Theory (SMT) in ... theories have formally opposed each other championed by authors ... forum for discussion. Soto and Sonnenschein, from Tufts University, ...
... , THURSDAY, April 14 (HealthDay News) -- ... target the new organ can develop accelerated narrowing of ... may lead to organ rejection. That,s the finding ... kidney biopsies from 99 kidney transplant patients -- 40 ...
... a statin before having major elective surgery reduces potentially ... an upcoming issue of the Journal of the ... than 230 million major elective surgeries are performed around ... develop kidney injury soon after surgery, often due to ...
... , Thursday, April 14 (HealthDay News) -- Just as the ... world,s languages also originated there and spread across the globe, ... analyzed the phonemes -- distinct units of sound that differentiate ... pattern mirrors that of human genetic diversity. As humans ...
Cached Medicine News:Health News:A Good Diet Includes Many Cancer-Fighting Foods: Expert 2Health News:Statins may protect against kidney complications following elective surgery 2Health News:Human Language Origins Traced to Africa, Study Finds 2
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
PDA version of the best-selling guide....
PDA application contains 15,000+ ICD-9-CM Diagnosis codes....
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Medicine Products: